R&D Why pharma’s future may run through your local blood centre With demand for cell and gene therapies (CGTs) growing rapidly, blood centres are indispensable collaborators.
R&D On US drug shortages and compounding pharmacies, with Shawn ... Shawn Hodges, CEO of Revelation Pharma, discusses the true state of drug shortages in the US at the moment and the role of compounding pharmacies.
R&D Seamless scale-up: Integrated manufacturing becomes the biop... Today, the demand for speed, quality, and scalability is pushing the industry towards a different model: integrated manufacturing.
R&D On inflammation, heart health, and GLP-1 possibilities, with... Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.
R&D On digital twins in rare disease research, with Piet van der... Piet van der Graaf, Senior VP at Certara discusses the potential of digital twins in rare diseases research.
R&D Changing Faces – Board of Directors and Advisory Boards - Oc... From high-profile resignations to the addition of seasoned executives and scientific leaders, last month saw a series of notable changes.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
